Burusnukul Prinyarat, Brennan Thomas D, Cupler Edward J
Department of Neurology, Oregon Health & Science University, Portland, OR 97239, USA.
J Clin Neuromuscul Dis. 2010 Dec;12(2):85-7. doi: 10.1097/CND.0b013e3181fcc109.
Forty percent to 50% of acetylcholine receptor antibody-seronegative patients with myasthenia gravis have muscle-specific receptor tyrosine kinase antibodies. Many muscle-specific receptor tyrosine kinase + myasthenia gravis patients remain refractory with conventional therapies. Rituximab is an anti-CD20 monoclonal antibody used in refractory B-cell disorders. Currently there is no standard dosing schedule for rituximab. We present two muscle-specific receptor tyrosine kinase + myasthenia gravis patients clinically refractory to conventional therapy who, after a single course of rituximab, became asymptomatic and discontinued all medication.
40%至50%的乙酰胆碱受体抗体血清阴性的重症肌无力患者存在肌肉特异性受体酪氨酸激酶抗体。许多肌肉特异性受体酪氨酸激酶阳性的重症肌无力患者对传统疗法仍有抵抗性。利妥昔单抗是一种用于难治性B细胞疾病的抗CD20单克隆抗体。目前利妥昔单抗尚无标准给药方案。我们报告了两名对传统治疗临床抵抗的肌肉特异性受体酪氨酸激酶阳性的重症肌无力患者，在接受单疗程利妥昔单抗治疗后，症状消失并停用了所有药物。
